Search for: [Abstract = "Invariably, for years, type 2 diabetes has been described as a global, social health problem, affecting approximately 10% of the world's population. A much broader and still growing health problem on a global scale consists in disorders of glucose and lipid metabolism with accompanying insulin resistance, which can lead to symptomatic type 2 diabetes and other serious health consequences. Among these consequences is the nonalcoholic fatty liver disease \(NAFLD\), which affects about 25% of the population, and it is estimated to become the most common indication for liver transplantation by 2030. Despite the availability of a wide range of antidiabetic drugs, a large proportion of patients struggle to achieve sufficient clinical improvement and reducing the risk of complications associated with T2D. This explains the high number of compounds being evaluated in clinical trials. Currently, there are no approved pharmacotherapies for treating NAFLD or metabolic disorders associated with prediabetic conditions, as pharmacological interventions in this area are not well\-established. While vanadium compounds are not considered primary pharmacotherapeutic options for metabolic disorders, their over 100\-year history of clinical applications and numerous preclinical evidence suggest their potential in antidiabetic action. Currently, the most promising direction of research i"]

Number of results: 1